שווי מצרפי של נכסים: aimimmuno.com (AIM)

The market price on the GURU.Markets platform, as confirmed by this chart, shows that the total assets of AIM ImmunoTech (AIM) amount to 8.43. AIM ImmunoTech (AIM) develops immune-boosting agents, yet faces intense pressure from pharma behemoths in the competition for government funding. The business relies on foreign patents, which remain vulnerable due to political strife and raw material supply chain issues. Meanwhile, the company strictly adheres to environmental waste disposal regulations.

As a biopharmaceutical innovator in the field of cancer and viral immunotherapy, AIM ImmunoTech (AIM) is accumulating resources, where the value of consolidated assets—reconstructed via daily ROA as the sum of equity and liabilities—objectively measures the scale of its operational base; for the investor, the trend of this metric serves as an indicator of the company's ability to sustain costly research and development amid tight monetary policy.